Drug intelligence / Profile preview

Lactobacillus paracasei CPU2306

Development stage: Preclinical
Lead developer: Shandong Provincial Third Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus paracasei CPU2306 is a specific probiotic strain being developed as a live biotherapeutic product (LBP) for the management of hyperuricemia and gout. Developed by the Shandong Provincial Third Hospital in collaboration with China Pharmaceutical University, this strain was selected for its high capacity to degrade purine nucleosides (such as adenosine and guanosine) and uric acid within the intestinal lumen. By reducing the availability of these precursors for absorption, the therapy lowers the systemic load of uric acid, thereby mitigating the risk of urate crystal formation in the joints. In addition to its direct metabolic activity, the strain may also help restore gut microbiota balance, which is often disrupted in patients with metabolic disorders. It is typically administered orally as a powder or capsule.

Other names: L. paracasei CPU2306

Beyond the preview

Go deeper on Lactobacillus paracasei CPU2306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus paracasei CPU2306.

Explore the full profile